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Skeletal muscle atrophy occurs as a side effect
of treatment with synthetic glucocorticoids
such as dexamethasone (DEX) and is a hallmark
of cachectic syndromes associated with in-
creased cortisol levels. The E3 ubiquitin ligase
MuRF1 (muscle RING finger protein 1) is tran-
scriptionally upregulated by DEX treatment.
Differentiated myotubes treated with DEX
undergo depletion of myosin heavy chain pro-
tein (MYH), which physically associates with
MuRF1. This loss of MYH can be blocked by in-
hibition of MuRF1 expression. When wild-type
and MuRF1/ mice are treated with DEX, the
MuRF1/ animals exhibit a relative sparing of
MYH. In vitro, MuRF1 is shown to function as
an E3 ubiquitin ligase for MYH. These data iden-
tify the mechanism by which MYH is depleted
under atrophy conditions and demonstrate
that inhibition of a single E3 ligase, MuRF1, is
sufficient to maintain this important sarcomeric
protein.
INTRODUCTION
The loss of skeletal muscle mass and strength are hall-
marks of several cachectic syndromes, including conges-
tive heart failure, chronic obstructive pulmonary disease
(COPD), and severe burns. Notably, several cachexias
are associated with increased cortisol levels (Anker
et al., 1997; Hasselgren, 1999; Hong and Forsberg,
1995; Wing and Goldberg, 1993); also, muscle atrophy is
a dose-limiting side effect of treatment with synthetic
glucocorticoids, complicating high-dose treatment with
these pharmacologic agents. Interestingly, hypercortiso-
lemia has recently also been shown to exacerbate the
atrophy-inducing effects of bed rest (Fitts et al., 2007). In
a cell culture system of muscle atrophy, it was demon-
strated that dexamethasone treatment induced the selec-
tive loss of myosin heavy chain protein (MYH) (Chromiak376 Cell Metabolism 6, 376–385, November 2007 ª2007 Elsevieand Vandenburgh, 1992). This study indicated that gluco-
corticoid treatment affects muscle integrity by increasing
protein breakdown of an important component of the sar-
comere. It has been further shown that MYH is selectively
depleted in myotube cultures treated with the atrophy-
inducing cytokine TNF together with interferon (Acharyya
et al., 2004) and that MYH is ubiquitinated in vivo in set-
tings of cardiac cachexia (Schulze et al., 2005), but the
mediator for these effects has not been elucidated.
A search for high-fidelity markers of the atrophy pheno-
type led to two genes, MAFbx (also called atrogin-1) (Bod-
ine et al., 2001; Gomes et al., 2001) and MuRF1 (muscle
RING finger protein 1) (Bodine et al., 2001), which have
been shown to be upregulated in at least 13 distinct
models of atrophy, validating them as reliable markers
for the atrophy phenotype (Bodine et al., 2001; Dehoux
et al., 2003; Glass, 2005; Krawiec et al., 2005; Latres et al.,
2005; Lee et al., 2004; Li et al., 2003, 2005; Sandri et al.,
2004; Wray et al., 2003). Both MuRF1 and MAFbx encode
E3 ubiquitin ligases, a large family of proteins that mediate
the ubiquitination of distinct protein substrates (Petroski
and Deshaies, 2005; Winston et al., 1999; Yamao, 1999).
MuRF1 is an enzyme of the RING-B box-coiled-coil
(RBCC) or tripartite motif (TRIM) family of proteins, which
exhibit intrinsic ubiquitin-conjugating activity. We previ-
ously reported the production of MuRF1/ mice (Bodine
et al., 2001). In the unperturbed state, they appear pheno-
typically normal; however, when examined 14 days post-
denervation, significantly less muscle mass was lost in
MuRF1/ animals in comparison to wild-type littermates
(Bodine et al., 2001).
There are two other MuRF family members, MuRF2 and
MuRF3. MuRF proteins localize to the sarcomere (Centner
et al., 2001), and it has been shown that MuRF1 associ-
ates with titin at the M band of the sarcomere, which has
been proposed to maintain stability of the sarcomeric M
line region (Gregorio et al., 2005; McElhinny et al., 2002).
In another study, using a yeast two-hybrid method, eight
myofibrillar proteins were shown to be binding partners
of MuRF1: titin, nebulin, the nebulin-related protein
NRAP, troponin I (TnI), troponin T (TnT), myosin light chain
2 (MLC-2), myotilin, and T-cap (Witt et al., 2005). In that
study, however, none of these proteins were implicatedr Inc.
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levels of interactors in MuRF1/ animals. However,
MuRF1 has been reported to function as an E3 ubiquitin
ligase that catalyzes the ubiquitination of troponin I in
cardiac myocytes (Kedar et al., 2004). Troponin I is there-
fore the only substrate previously reported for MuRF1, and
it is not perturbed in skeletal muscle by the deletion of
MuRF1 (Witt et al., 2005) or in myotubes by treatment
with dexamethasone (B.A.C. and D.J.G., unpublished
data). Therefore, it is still of interest to understand how
MuRF1 modulates the atrophy phenotype.
RESULTS
Dexamethasone Induces a Loss
of Myosin Heavy Chain and an Increase
in MuRF1
To identify sarcomeric proteins that are perturbed under
atrophy conditions, a previously described cell culture
model of muscle atrophy was employed, in which
C2C12 myotubes are treated with the synthetic glucocor-
ticoid dexamethasone (DEX), resulting in phenotypic atro-
phy as determined by measuring myotube diameter and
the loss of insoluble protein (Stitt et al., 2004). C2C12 my-
otubes were differentiated for 3 days and then treated for
24 hr with DEX. The cells were lysed, and the insoluble
fraction, enriched for sarcomeric proteins, was homoge-
nized. Equal amounts of insoluble material from the con-
trol versus DEX-treated cells were run on gels, which
were subsequently stained with Coomassie blue. There
was a single obvious difference in the protein pattern
from the DEX-treated myotubes as compared to un-
treated myotubes (Figure 1A): the most abundantly
stained protein, of nearly 250 kDa, was substantially re-
duced after DEX treatment. This protein was consistent
in size with myosin heavy chain (MYH). To determine
whether MYH was indeed the protein observed on the
Coomassie-stained gel, a similar experiment was per-
formed, and duplicate membranes were prepared and im-
munoblotted with antibodies recognizing isoforms of
MYH. A pan-specific antibody detecting ‘‘fast’’ MYH iso-
forms (MYH1, MYH2, MYH3, MYH4, and MYH8, found
in ‘‘type II’’ or ‘‘fast-twitch’’ fibers) showed a clear reduc-
tion in the amount of fast MYH isoforms after 24 or 32
hours of DEX treatment (Figure 1B). Densitometric analy-
sis of three separate replicates revealed consistent de-
creases at each time point (Figure 1C). An antibody de-
tecting the single ‘‘slow’’ isoform of MYH (MYH7, found
in ‘‘type I’’ fibers) showed similar decreases after DEX
treatment (Figure 1B; replicates quantified in Figure 1C).
To determine whether other sarcomeric proteins were
similarly lost in this model, levels of actin were determined;
these were found to be unaltered during the treatment
period (Figure 1B).
The E3 ubiquitin ligase MuRF1 has been shown to be
transcriptionally induced in at least 13 models of muscle
atrophy (Glass, 2005). The amount of MuRF1 protein pres-
ent after DEX treatment was analyzed and demonstrated
to be increased, coincident with the decrease in MYHCell Mlevels (Figure 1B, third panel). It was necessary to deter-
mine whether the change in MYH protein could be ex-
plained by alterations in Myh mRNA levels, as opposed
to an increase in protein turnover. The mRNA levels of
the five distinct Myh isoforms known to be expressed in
C2C12 myotubes were analyzed (Figure 1D). Only one of
the mRNAs encoding a Myh gene, Myh3, was found to
be decreased; Myh1 and Myh4 mRNA levels were unper-
turbed, and Myh7 and Myh8 levels actually increased
upon DEX treatment (Figure 1D). The data therefore indi-
cate that the decreases observed in the protein levels
are due to posttranscriptional events.
MuRF1 Physically Associates with Myosin
Heavy Chain
To determine whether MuRF1 interacts with the MYH pro-
tein and might therefore have a means to perturb the turn-
over of MYH, C2C12 myoblast cells were infected with
a retrovirus encoding human MuRF1 protein (hMuRF1)
fused to the TAP epitope tag at the COOH terminus
(C-TAP-hMuRF1) (Angrand et al., 2006). Infected cells
were differentiated into myotubes for 3 days. As a control,
uninfected C2C12 myotubes were also analyzed. Lysates
were prepared and MuRF1 was immunoprecipitated using
IgG Sepharose to bind to the protein A epitope on the TAP
tag; the resulting immunoprecipitates were then immuno-
blotted for MYH using the pan-specific antibody recogniz-
ing MYH isoforms found in type II, fast fibers (Figure 1E).
MuRF1 was found to be capable of immunoprecipitating
MYH, whereas significantly less MYH was found when
control lysates were analyzed. Total levels of MYH were
determined by western blot and were found to be equiva-
lent between control and C-TAP-hMuRF1 cells (Figure 1E).
These data demonstrate that MuRF1 physically interacts
with MYH.
Myosin Heavy Chain Isoform Loss Is Proteasome
Dependent
Much of the protein degradation seen during skeletal
muscle atrophy is due to the ATP-dependent ubiquitin
proteasome system (Krawiec et al., 2005; Tawa et al.,
1997). Two proteasome inhibitors, MG132 and epoxomi-
cin (EPOX), were used to determine whether the loss of
MYH observed after DEX treatment could be inhibited
by blocking proteasome-mediated protein turnover.
C2C12 myotubes were treated with DEX in the presence
or absence of either MG132 or EPOX, and MYH protein
levels were analyzed. DEX treatment resulted in the loss
of both fast and slow MYH isoforms, but treatment with ei-
ther MG132 or EPOX in addition to DEX rescued the de-
crease in MYH protein observed after DEX treatment
alone (Figure 2A, panels 1 and 2, compare lane 2 with
lanes 3 and 4). MuRF1 protein was increased after treat-
ment with DEX but remained unchanged by proteasome
inhibition alone (Figure 2A). Actin levels were unperturbed
by any of the treatments, allowing actin to serve as a load-
ing control (Figure 2A). These data were confirmed in three
replicate plates for each experiment and quantified by
densitometry (Figure 2B). These findings indicate thatetabolism 6, 376–385, November 2007 ª2007 Elsevier Inc. 377
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MYH Is a MuRF1 SubstrateFigure 1. Dexamethasone Induces an Increase in MuRF1 and a Concomitant Decrease in MYH
Myotubes were differentiated for 3 days prior to dexamethasone (DEX) treatment.
(A) Detergent-insoluble protein samples were analyzed by SDS-PAGE and subsequent Coomassie staining. Protein lysates were from untreated (lane
1) and 24 hr DEX-treated (lane 2) myotubes. The arrow indicates the loss of a protein with a molecular weight of 250 kDa.
(B) Analysis of myosin heavy chain (MYH) isoforms by immunoblotting (IB). Top panel: ‘‘fast,’’ type II isoforms (MYH(fast)); second panel: ‘‘slow,’’ type I
isoforms (MYH (slow)); third panel: MuRF1; bottom panel: actin. On each panel, lysates from untreated () and 24 or 32 hr DEX-treated myotubes are
presented. A high-molecular-weight ladder consistent with ubiquitinated material is visible in the DEX-treated MYH lanes, coincident with the loss of
MYH protein at 250 kDa.
(C) Densitometric analysis of MYH isoforms in (B), shown as mean density (in arbitrary units) from three replicate plates. Error bars in (C) and (D) rep-
resent standard error of the mean (SEM).
(D) MuRF1 and individual Myh mRNAs from untreated (CON 24 and CON 32) and DEX-treated (DEX 24 and DEX 32) myotubes. RNA analysis was
performed by qPCR. Graphs depict the mean relative fold changes and are representative of three replicate plates.
(E) MuRF1 associates with MYH in C2C12 myotubes. IB analysis of MYH coimmunoprecipitated (IP) with C-TAP-hMuRF1 is presented. C-TAP-
hMuRF1 is detected as a result of the affinity of the protein A portion of the TAP tag for IgG. Total levels of MYH from the lysates are shown in the
top panel.378 Cell Metabolism 6, 376–385, November 2007 ª2007 Elsevier Inc.
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MYH Is a MuRF1 SubstrateFigure 2. Dexamethasone-Induced Loss of Myosin Heavy Chain Is Blocked by Proteasome Inhibitors
(A) IB analysis of MYH isoforms, MuRF1, and actin after DEX treatment in the presence (+) or absence () of MG132 or epoxomicin (EPOX).
(B) Densitometric analysis of MYH isoforms from (A) shown as mean density (in arbitrary units) from three replicate plates. Error bars represent SEM.proteasome-dependent activity is required for the loss of
MYH induced by DEX treatment.
MuRF1 Is Required for the Loss of Myosin Heavy
Chain Protein
Given that MuRF1 is responsible for a significant amount
of the muscle loss observed under atrophy conditions
(Bodine et al., 2001; Cai et al., 2004), our findings that
MuRF1 and MYH physically interact and that inhibition
of the proteasome rescues the loss of MYH during DEX
treatment prompted us to determine whether MuRF1 is re-
quired for the decrease in MYH levels during DEX treat-
ment. To answer this question, C2C12 myotubes were in-
fected with an adenovirus expressing a short hairpin RNA
(shRNA) recognizing the sequence encoding MuRF1
(shMuRF1) or a control virus expressing a noncoding
shRNA (shCON). Twenty-four hours after infection, cells
were treated with DEX. After an additional 24 hr post
DEX treatment, the cells were lysed and RNA was ex-
tracted. To determine the specificity of the MuRF1 shRNA,
mRNA levels of the three MuRF family members, MuRF1,
MuRF2, and MuRF3, were analyzed by quantitative PCR
(qPCR). MuRF1 mRNA levels were significantly decreased
by infection with shMuRF1 to less than 20% of that ob-
served in control myotubes (Figure 3C). As expected,
MuRF1 mRNA levels were increased, by nearly 70%, after
DEX treatment (Figure 3C). When shMuRF1 was intro-
duced into myotubes and the cells were subsequentlyCell Metreated with DEX, MuRF1 mRNA levels were reduced to
below 50% of control levels (Figure 3C). Analysis of
MuRF2 and MuRF3 mRNA levels revealed that neither
one was affected by infection with shMuRF1 (Figure 3C).
A duplicate experiment was performed, and the cells
were lysed for immunoblot analysis. Myotubes that were
treated with DEX in the presence of shCON demonstrated
the same decrease in MYH protein and the same increase
in MuRF1 protein observed in Figure 1 and Figure 2; myo-
tubes treated with only shCON served as the negative
control in this experiment (Figure 3A, compare lanes 1
and 2). In contrast, when myotubes were treated with
shMuRF1, there was a significant decrease in MuRF1
levels in comparison to the shCON-treated cells; further-
more, while DEX slightly increased MuRF1 protein levels in
these cells, the final level was less than that observed
in control myotubes (Figure 3A, compare lanes 4 and 1).
In these DEX-treated myotubes, in which MuRF1 levels
were inhibited by shMuRF1 expression, there was almost
no loss of either fast or slow MYH (Figure 3A, compare
lanes 4 and 2). Actin protein levels remained unchanged,
allowing actin to serve as a loading control (Figure 3A,
panel 4).
The results of three replicate plates from a single exper-
iment were quantified, confirming that MuRF1 is required
for the loss of MYH protein (Figure 3B). To determine
whether the changes in MYH protein levels were due to
alterations in mRNA, Myh isoform mRNA was determinedtabolism 6, 376–385, November 2007 ª2007 Elsevier Inc. 379
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MYH Is a MuRF1 SubstrateFigure 3. MuRF1 Is Necessary for the Dexamethasone-Induced Loss of Myosin Heavy Chain in C2C12 Myotubes
Myotubes were infected 2 days postdifferentiation with adenovirus expressing a short hairpin RNA directed against MuRF1 (shMuRF1) or a control
virus (shCON) targeting no known mammalian sequence. Twenty-four hours after infection, the myotubes were treated with DEX for an additional 24 hr.
(A) IB analysis of MYH isoforms, MuRF1, and actin after shRNA knockdown of MuRF1 and/or DEX treatment. The myotubes treated with shCON alone
(lane 1) serve as the negative control. DEX (lane 2) induces the loss of fast (MYH(fast)) and slow (MYH(slow)) myosin heavy chain isoforms; this loss of
MYH isoforms is blocked by shMURF1 (lane 4). Treatment with shMURF1 does not affect MYH levels but does reduce MuRF1 to levels below that seen
in control (compare lane 3 to lane 1).
(B) Densitometric analysis of MYH isoforms from (A) shown as mean density (in arbitrary units) from three replicate plates. *p < 0.01 versus shCON +
DEX by ANOVA and Tukey’s post hoc test. Error bars in (B)–(D) represent SEM.
(C) mRNA levels of the three MuRF family members, MuRF1, MuRF2, and MuRF3, analyzed by qPCR after MuRF1 knockdown and DEX treatment.
Graphs depict mean relative fold changes and are representative of three replicate plates. Each mRNA expression level was determined relative to
the mean expression level of that mRNA in control cells. *p < 0.01 versus shCON by ANOVA and Tukey’s post hoc test.
(D) Individual Myh mRNAs from MuRF1 knockdown and DEX-treated myotubes. Graphs depict mean relative fold changes and are representative of
three replicate plates.by quantitative TaqMan PCR. The mRNA levels of Myh1
and the single slow isoform, Myh7, were unaltered by
DEX or by shRNA knockdown of MuRF1; the isoforms
Myh3, Myh4, and Myh8 were all increased between 1.5-
and 3-fold after DEX treatment alone, a change that was
not affected by MuRF1 knockdown and therefore does
not account for the sparing effect of MuRF1 inhibition
(Figure 3D). These data indicate that the DEX-induced
MYH loss in C2C12 myotubes is posttranscriptional and380 Cell Metabolism 6, 376–385, November 2007 ª2007 Elsevthat MuRF1 does not influence the mRNA levels of the
Myh isoforms analyzed. Therefore, inhibition of MuRF1 ex-
pression is sufficient to block the posttranscriptional loss
of MYH observed after DEX treatment.
Dexamethasone-Induced MYH Loss Is Attenuated
in MuRF1/ Mice
To determine whether the sparing of MYH loss seen in
DEX-treated C2C12 myotubes after MuRF1 knockdownier Inc.
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scribed MuRF1 null (MuRF1/) mouse model (Bodine
et al., 2001). Wild-type (WT) mice were treated with DEX
or saline (n = 9 and n = 8, respectively) for 14 days, as
were MuRF1/mice (n = 6 and n = 7, respectively). Gas-
trocnemius muscle weights were taken and normalized to
the animals’ starting body weight. Equal amounts of pro-
tein homogenates were analyzed by immunoblot for fast
MYH isoforms, as well as for sarcomeric actin. MYH levels
were decreased when comparing WT saline- and DEX-
treated samples (Figure 4A). Furthermore, there was a
15% loss of mass in DEX-treated WT gastrocnemius mus-
cles in comparison to controls (data not shown). In con-
trast, the levels of actin did not appear to be consistently
altered between groups (Figure 4A).
MYH loss was compared relative to actin by densito-
metric analysis of the immunoreactive bands, revealing
a nearly 10% loss of MYH relative to actin in DEX-treated
WT mice (Figure 4B). In contrast, the MYH:actin ratio in
DEX-treated MuRF1/ animals increased significantly
as compared to either WT or MuRF1/ mice treated
with saline or to WT mice treated with DEX (1.23 ± 0.06
versus 1.01 ± 0.04, 0.91 ± 0.05, and 1.02 ± 0.03, respec-
tively; p < 0.01) (Figure 4B). The increase in MYH relative to
actin in MuRF1/mice treated with DEX was greater than
29% when compared to WT animals treated with DEX
(Figure 4B; 9% loss in WT + DEX versus 20% increase in
MuRF1/ + DEX). Despite the sparing of MYH, MuRF1-
Figure 4. Myosin Heavy Chain Is Relatively Spared in MuRF1
Null Animals Undergoing DEX-Induced Atrophy
Homozygous MuRF1 knockout (KO) mice and wild-type (WT) control
mice were treated for 14 days with 1 mg/kg DEX or saline.
(A) IB analysis of MYH and sarcomeric actin from gastrocnemius mus-
cle was performed for all animals in the study. A representative blot is
shown.
(B) The immunoreactive bands were subjected to densitometric anal-
ysis, and the ratio of MYH to actin was determined. The mean MYH:
actin ratio was plotted for WT and KO mice treated with DEX as the
percent change from WT mice treated with saline. *p < 0.01 versus
WT saline-treated mice by ANOVA and Tukey’s post hoc test. Error
bars represent SEM.Cell Mdeficient muscle mass was spared by only 3% relative
to WT muscle after DEX treatment (data not shown).
These findings highlight a preferential sparing of MYH in
comparison to the sarcomeric protein actin in DEX-treated
mice deficient for MuRF1, indicating the specific role of
MuRF1 in the regulation of MYH.
Myosin Heavy Chain Protein Is Ubiquitinated
by MuRF1 In Vitro
To determine whether MYH protein is a substrate for
MuRF1 ubiquitin ligase activity, in vitro ubiquitination as-
says were performed utilizing purified recombinant GST-
His-hMuRF1 protein, purified myosin II protein from rabbit
skeletal muscle, yeast E1, recombinant hUbcH5c, and
His6-biotin-hUB. Reactions were conducted with or with-
out myosin present, and the results were analyzed by im-
munoblotting for ubiquitin using streptavidin-conjugated
HRP (Figure 5). When increasing concentrations of GST-
His-hMuRF1 were used in the assay, a corresponding
increase in the amount of ubiquitinated product was
observed above the molecular weight for myosin
(Figure 5A). In control lanes, where no myosin was in-
cluded, there was significantly less ubiquitinated material
visible above the molecular weight for myosin, indicating
that the increase in signal after addition of MYH is caused
not by auto-ubiquitinated GST-His-hMuRF1 but by ubiq-
uitination of myosin (Figure 5A). We next performed
a time course of myosin ubiquitination using a single con-
centration of 50 nM GST-His-hMuRF1 (Figure 5B). As the
reaction proceeded, we observed an increased accumu-
lation of ubiquitinated products above the molecular
weight of myosin that was not observed in lanes that did
not contain MYH (Figure 5B). These results indicate that
MuRF1 can directly ubiquitinate myosin in vitro.
DISCUSSION
MuRF1 was previously demonstrated to be transcrip-
tionally upregulated in multiple models of skeletal muscle
atrophy (Glass, 2005). When MuRF1/ animals are sub-
jected to atrophy conditions—via either denervation or
the coexpression of a constitutively active form of the
NF-kB activator IKK—significantly less muscle is lost
than in MuRF1+/+ control mice, indicating that MuRF1 is
more than a marker of the atrophy process, it is in part re-
sponsible for the increased protein turnover that occurs
during atrophy (Bodine et al., 2001; Cai et al., 2004).
The question that remained was clear: How does
MuRF1 mediate skeletal muscle atrophy? Several impor-
tant studies have demonstrated that MuRF1 can interact
with key sarcomeric proteins, including titin at the M
band of the sarcomere, which has been proposed to main-
tain stability of the sarcomeric M line region (Gregorio
et al., 2005; McElhinny et al., 2002), as well as nebulin,
NRAP, TnI, TnT, MLC-2, myotilin, and T-cap, but no differ-
ence was seen in these proteins when MuRF1/ and con-
trol animals were compared (Witt et al., 2005), nor have
there been reports of these proteins being perturbed in
models of atrophy. Of all the previously identifiedetabolism 6, 376–385, November 2007 ª2007 Elsevier Inc. 381
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a ubiquitination substrate of MuRF1 in cardiac myocytes
(Kedar et al., 2004). However, in our studies, TnI levels in
skeletal myotubes were not altered by DEX treatment or
by inhibition of MuRF1 (data not shown), consistent with
the previous report comparing troponin levels in WT and
MuRF1 null mice (Witt et al., 2005).
To identify an atrophy-relevant MuRF1 substrate, this
study initially focused on the synthetic glucocorticoid
DEX as a method to induce myotube atrophy in cell cul-
ture; it has previously been shown that DEX treatment
can induce atrophy and the upregulation of MuRF1 and
MAFbx in myotubes (Latres et al., 2005; Sacheck et al.,
2004) and the selective loss of MYH by increasing protein
Figure 5. MuRF1 Ubiquitinates Myosin Heavy Chain Protein
In Vitro
MYH (1 mM) was incubated with increasing concentrations of GST-His-
hMuRF1 for 1 hr or with 50 nM GST-His-hMuRF1 over a time course.
(A) IB analysis of in vitro myosin ubiquitination with increasing amounts
of GST-His-hMuRF1. Reactions were carried out for 1 hr at room tem-
perature.
(B) Time course of in vitro myosin ubiquitination by 50 nM GST-
hMuRF1. All reactions were performed at room temperature. MYH-
Ub indicates ubiquitinated MYH, which is only in evidence in the pres-
ence of MYH; MuRF-Ub indicates auto-ubiquitinated MuRF1, which is
apparent in the lanes with or without MYH.382 Cell Metabolism 6, 376–385, November 2007 ª2007 Elsevturnover (Chromiak and Vandenburgh, 1992). In the pres-
ent study, a Coomassie-stained gel comparing lysates
from control and DEX-treated myotubes demonstrated
that a single protein, consistent in molecular weight with
MYH, was highly abundant in control cells but much less
evident in lysates from DEX-treated myotubes. An immu-
noblot confirmed that the protein was MYH, and anti-
bodies that discriminate between the slow and fast iso-
forms of the protein showed that both classes were
significantly affected by the treatment. The decrease in
MYH was found to be coincident with an increase in
MuRF1 protein levels in these myotubes; this last point
is noteworthy because most prior studies focused on
MuRF1 mRNA levels alone. An indication that MuRF1
and MYH might be in a common pathway is that the two
proteins directly interact—epitope-tagged MuRF1 protein
coimmunoprecipitated with MYH protein. Also suggestive
is the fact that MYH levels can be maintained when the
ubiquitin-proteasome system is inhibited by the use of
either of two proteasome inhibitors, indicating that MYH
is being degraded via the proteasome. The demonstration
that selective inhibition of MuRF1, using MuRF1-specific
shRNA that does not inhibit other MuRF family members,
is sufficient to maintain MYH levels, even in the presence
of DEX treatment, implicates MuRF1 directly as the key
modulator of MYH levels.
Mice that are null for MuRF1 have been described pre-
viously (Bodine et al., 2001). These animals were used to
assess whether the absence of MuRF1 was sufficient to
spare MYH levels under atrophy conditions in vivo. Both
WT and MuRF1/ mice were treated with DEX for 2
weeks. In this experimental setting, MYH was decreased
in WT muscle relative to total protein, but not in the lysates
from MuRF1/ muscle. When the relative changes in
MYH were assessed, the results were more striking: in
WT animals, MYH was lost to a 10% greater degree
than actin under conditions of DEX treatment, whereas
in the MuRF1 null animals, there was an increase in
MYH relative to actin, indicating that myosin is preferen-
tially spared under atrophy conditions in the absence of
MuRF1. Interestingly, in contrast to denervation or the
upregulation of constitutively active IKK, in which MuRF1
deletion has been previously shown to block atrophy
(Bodine et al., 2001; Cai et al., 2004), DEX treatment of
MuRF1 null animals did not result in a statistically signifi-
cant decrease in atrophy in comparison to DEX treatment
of WT animals. This indicates that sparing of MYH is not
sufficient to avoid DEX-induced atrophy, that there are ap-
parently distinct atrophy mechanisms engaged upon DEX
treatment in comparison to denervation and IKK upregula-
tion, and that loss of MuRF1 is not sufficient to stop these.
The in vivo data are reminiscent of studies on humans
treated with high doses of steroids. A corticosteroid-
induced myopathy has been reported in which there is
a preferential loss of thick filaments, containing myosin,
and a relative preservation of thin, actin-containing fila-
ments (Hanson et al., 1997).
Direct biochemical evidence as to the mechanism by
which MuRF1 causes the turnover of MYH is providedier Inc.
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uitin ligase for MYH in an in vitro ubiquitination reaction
(Figure 5). This study therefore provides evidence that
the critical sarcomeric protein MYH is a substrate for
MuRF1 and that loss of MuRF1 is sufficient to maintain
MYH levels during muscle atrophy.
These findings suggest a model as to the order of sarco-
meric protein breakdown during muscle atrophy. Since
MYH is lost out of proportion to other contractile proteins
during atrophy in WT animals and since other contractile
apparatus components seem to be maintained in
MuRF1 null animals, the data suggest that MYH degrada-
tion occurs quite early in the sarcomere breakdown pro-
cess, such that blocking this step protects sarcomeric in-
tegrity. The fact that MYH is lost to a greater degree than
other proteins also suggests a particular model of atrophy
in which a single key protein is removed, disrupting the in-
tegrity of the system without necessarily having to remove
each individual protein to the same extent. Also, the data
indicate that inhibition of other proteases, such as the cal-
pains, may not be required to maintain MYH levels, though
it is still possible that MuRF1 perturbs calpain or other pro-
teolysis pathways by some additional mechanism. The
finding of a single MuRF1 substrate that is perturbed
during skeletal muscle atrophy does not eliminate the pos-
sibility that MuRF1 acts on additional important sub-
strates—and the prior report that a MuRF family member
can perturb serum response factor (SRF) (Lange et al.,
2005) makes one wonder whether MuRF1 also functions
away from the sarcomere during atrophy. However, the
demonstration in the present study that one of the main
components of the sarcomere, MYH, can be rescued
solely by eliminating MuRF1 increases focus on the con-
tractile apparatus as the target for MuRF1 activity during
skeletal muscle atrophy and provides the basis for future
studies to determine the order and mechanism of protein
breakdown of the sarcomere.
EXPERIMENTAL PROCEDURES
Cell Culture and Treatment
C2C12 myoblasts (ATCC) were cultured and differentiated as de-
scribed previously (Rommel et al., 1999). For shRNA experiments, cells
were infected with adenovirus on day 2 postdifferentiation and treated
with DEX for 24 hr starting on day 3. When proteasome inhibitors were
used, they were added for the last 8 hr before harvesting cells on day 4.
For the MuRF1/MYH coimmunoprecipitation experiment, C-termi-
nal TAP-tagged MuRF1 (C-TAP-hMURF1) was stably expressed in
C2C12 myoblasts by retrovirally mediated gene transfer. Cells were
differentiated into myotubes for 3 days. TAP-tagged MuRF1 and asso-
ciated proteins were coimmunoprecipitated as described previously
(Angrand et al., 2006).
Biochemicals and Antibodies
Myotubes were treated with 100 mM DEX (Sigma-Aldrich) dissolved in
ethanol. MG132 and EPOX (Calbiochem) were dissolved in DMSO and
used at 10 mM and 100 nM, respectively. Mouse monoclonal anti-
bodies against fast MYH isoforms (MY32), the slow MYH isoform
(NOQ7.5.4D), and actin (catalog #A2103) were from Sigma-Aldrich.
Hybridoma cell supernatant containing anti-MuRF1 monoclonal anti-
bodies (Regeneron Pharmaceuticals), donkey anti-mouse HRP (Rock-
land Biochemicals), IRDye 800CW goat anti-mouse IgG and IRDye 680Cell Mgoat anti-rabbit IgG (Li-Cor Biosciences), and benzonase (EMD Biosci-
ences) were used.
Western Blotting
Myotubes were scraped into PBS containing 1% NP40, 1 mM EDTA,
10 mM NaF, and protease inhibitors (lysis buffer). Myotube homoge-
nates were rocked at 4 degrees for 15 min and centrifuged for
10 min at 13,000 rpm. The supernatant was collected, and the insolu-
ble material was resuspended in 10% glycerol, 30 mM KCl, 20 mM Tris
(pH 7.6), 2 mM MgCl2, 2 mM DTT, 2 mM NaF in H2O containing benzo-
nase at 2.5 kU/ml. Samples were homogenized and incubated on ice
for 15 min. Protein concentrations of insoluble suspensions were as-
sayed by BCA Protein Assay Kit (Pierce). Samples were solubilized
in SDS-PAGE sample buffer, and equal amounts of protein were
loaded per lane of 4%–20% SDS polyacrylamide gels and transferred
onto PVDF membranes. Membranes were blocked in TBS with 5%
(w/v) milk powder. Primary and secondary antibodies were incubated
in TBS with 0.1% Tween 20 and 2.5% milk. Immunoreactivity was de-
tected by ECL and exposed to film or imaged with a Li-Cor Odyssey
imaging system.
For MuRF1 coimmunoprecipitation experiments, C2C12 myotubes
transduced retrovirally with an expression cassette encoding C-TAP-
hMURF1 were scraped into PBS containing 1% NP40, 1 mM EDTA,
10 mM NaF, and protease inhibitors. Human IgG Sepharose was
added to 2 ml of lysate (1 mg protein/ml). Uninfected C2C12 myotube
lysates at the same protein concentration were used as a negative
control. Membranes were probed with anti-MYH (fast) antibody
(Sigma) to corroborate coimmunoprecipitation with c-TAP-hMuRF1.
RNA Analysis
RNA was isolated using TRI reagent (Molecular Research Center,
Inc.) per the manufacturer’s protocol. cDNA synthesis was performed
using a QIAGEN QuantiTect kit. qPCR was performed using an Ap-
plied Biosystems 7900HT Real-Time PCR machine. The TaqMan
probe sets MuRF1 (Mm01185221_m1), MuRF2 (Mm01292963_g1),
MuRF3 (Mm00491305_m1), MYH1 (Mm01332500_gH), MYH2 (Mm00
454991_m1), MYH3 (Mm01332469_g1), MYH4 (Mm01332541_m1),
MYH7 (Mm00600555_m1), and MYH8 (Mm00838799_g1) were pur-
chased from Applied Biosystems.
Adenovirus and RNAi
A shRNA corresponding to the sequence 50-GAACATGGACTACTT
TACT-30 within mouse MuRF1 was designed according to Invitrogen’s
BLOCK-iT adenoviral expression system. A control viral construct tar-
geting no known RNA sequence was similarly assembled. The adeno-
viral expression constructs were sent to Welgen, Inc. (Worcester, MA,
USA) for production and purification. The purified viruses were used at
a final concentration of 2.4 3 107 pfu/ml.
In Vitro Ubiquitination
For the in vitro ubiquitination assay, yeast E1, human recombinant
UbcH5c, and human N-terminal-hexahistidine-tagged biotinylated
ubiquitin (His6-biotin-hUB) were purchased form Boston Biochem,
Inc.; GST-His-hMuRF1 was bacterially expressed and purified by
Blue Sky Biotech, Inc.; and MYH type II protein, purified from rabbit
skeletal muscle, was purchased from Cytoskeleton, Inc. The reaction
was carried out by addition of 125 nM E1; 4 mM UbcH5c; 5 mM His6-
biotin-hUB; 5, 10, 20, or 50 nM GST-His-hMuRF1; and 1 mM myosin
to the reaction buffer (50 mM HEPES [pH 7.5] containing 5 mM MgATP
solution [Boston Biochem, Inc] and 0.6 mM DTT). GST-His-hMuRF1
was preincubated for 30 min on Reacti-Bind anti-GST coated plates
(Pierce); reactions were carried out for 1 hr at room temperature or in
a time course and ended by transfer of the reaction mix to a tube,
addition of SDS-PAGE sample buffer, and heating. Reactions were
run in 4%–12% Bis-Tris gels with 13 MES running buffer (Invitrogen)
and transferred to PVDF membranes for immunoblotting with strepta-
vidin-conjugated horseradish peroxidase (Pierce).etabolism 6, 376–385, November 2007 ª2007 Elsevier Inc. 383
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MuRF1 knockout (MuRF1/) mice were generated as described pre-
viously (Bodine et al., 2001). MuRF1/ mice and WT littermates
(3 months old, 25–30 g) were maintained on standard chow at a con-
stant temperature (21C) under a 12 hr/12 hr artificial light/dark cycle
with unlimited access to water. DEX or saline vehicle was continuously
infused via dorsally implanted osmotic minipumps (Alzet, model 2002)
at 1 mg/kg for 14 days. At the completion of the experiment, the mice
were sacrificed with CO2 followed by cervical dislocation. Gastrocne-
mius muscles were removed, weighed, and frozen in liquid nitrogen.
Homogenates were prepared in lysis buffer using a QIAGEN bead
homogenizer.
Statistical Analyses
Differences between groups were analyzed using one-way ANOVA for
all experiments. Significance was determined by Tukey’s post hoc
test. Values were considered significant at p < 0.01.
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